title: Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
abstract: This 56-week, randomized, placebo-controlled trial examined the efficacy and safety of naltrexone plus bupropion as an adjunct to intensive behavior modification (BMOD). A total of 793 participants (BMI = 36.5 ± 4.2 kg/m²) was randomly assigned in a 1:3 ratio to: (i) placebo + BMOD (N = 202); or (ii) naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD (i.e., NB32 + BMOD; N = 591). Both groups were prescribed an energy-reduced diet and 28 group BMOD sessions. Co-primary end points were percentage change in weight and the proportion of participants who lost ≥5% weight at week 56. Efficacy analyses were performed on a modified intent-to-treat population (ITT; i.e., participants with ≥1 postbaseline weight while taking study drug (placebo + BMOD, N = 193; NB32 + BMOD, N = 482)). Missing data were replaced with the last observation obtained on study drug. At week 56, weight loss was 5.1 ± 0.6% with placebo + BMOD vs. 9.3 ± 0.4% with NB32 + BMOD (P < 0.001). A completers analysis revealed weight losses of 7.3 ± 0.9% (N = 106) vs. 11.5 ± 0.6% (N = 301), respectively (P < 0.001). A third analysis, which included all randomized participants, yielded losses of 4.9 ± 0.6 vs. 7.8 ± 0.4%, respectively (P < 0.001). Significantly more NB32 + BMOD- vs. placebo + BMOD-treated participants lost ≥5 and ≥10% of initial weight, and the former had significantly greater improvements in markers of cardiometabolic disease risk. NB32 + BMOD was generally well tolerated, although associated with more reports of nausea than placebo + BMOD. The present findings support the efficacy of combined naltrexone/bupropion therapy as an adjunct to intensive BMOD for obesity.
authors.affiliation: Department of Psychiatry, Center for Weight and Eating Disorders, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. wadden@mail.med.upenn.edu
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Wadden
authors.forename: John P
authors.initials: JP
authors.lastname: Foreyt
authors.forename: Gary D
authors.initials: GD
authors.lastname: Foster
authors.forename: James O
authors.initials: JO
authors.lastname: Hill
authors.forename: Samuel
authors.initials: S
authors.lastname: Klein
authors.forename: Patrick M
authors.initials: PM
authors.lastname: O'Neil
authors.forename: Michael G
authors.initials: MG
authors.lastname: Perri
authors.forename: F Xavier
authors.initials: FX
authors.lastname: Pi-Sunyer
authors.forename: Cheryl L
authors.initials: CL
authors.lastname: Rock
authors.forename: Janelle S
authors.initials: JS
authors.lastname: Erickson
authors.forename: Holly N
authors.initials: HN
authors.lastname: Maier
authors.forename: Dennis D
authors.initials: DD
authors.lastname: Kim
authors.forename: Eduardo
authors.initials: E
authors.lastname: Dunayevich
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D001521:Behavior Therapy / Q000379:methods; D016642:Bupropion / Q000008:administration & dosage* / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage* / Q000009:adverse effects; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D009765:Obesity / Q000628:therapy*; D010919:Placebos; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D009292:Narcotic Antagonists; D010919:Placebos; D016642:Bupropion; D009271:Naltrexone